Eosinophilic oesophagitis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 18 Jun 2026 04:07:30 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Eosinophilic oesophagitis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on BP1.7881 for Adults with Eosinophilic Esophagitis https://clinicaltrials.eu/trial/study-on-bp1-7881-for-adults-with-eosinophilic-esophagitis/ Mon, 04 May 2026 07:53:00 +0000 https://clinicaltrials.eu/trial/study-on-bp1-7881-for-adults-with-eosinophilic-esophagitis/ This clinical trial is focused on studying eosinophilic esophagitis, a condition where a type of white blood cell called eosinophil builds up in the esophagus, leading to inflammation and difficulty swallowing. The trial will evaluate a new treatment called BP1.7881A, which is taken as an orodispersible tablet, meaning it dissolves in the mouth. The purpose of the study is to assess the effectiveness and safety of BP1.7881A in treating adults with eosinophilic esophagitis.

Participants in the study will be randomly assigned to receive either the BP1.7881A tablet or a matching orodispersible placebo tablet. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are unbiased. The trial will last for a period of 12 weeks, during which participants will undergo regular check-ups and assessments to monitor changes in their condition.

The main goal of the trial is to observe any changes in the number of eosinophils in the esophageal tissue, which will be measured through biopsies. Additionally, the study will track improvements in symptoms such as difficulty swallowing and other related issues. Participants will be asked to complete questionnaires and undergo endoscopic procedures to help gather this information. The trial aims to provide valuable insights into the potential benefits of BP1.7881A for individuals with eosinophilic esophagitis.

]]> Study on Etrasimod Arginine for Patients with Ulcerative Colitis, Alopecia Areata, Atopic Dermatitis, and Eosinophilic Esophagitis https://clinicaltrials.eu/trial/study-on-etrasimod-arginine-for-patients-with-ulcerative-colitis-alopecia-areata-atopic-dermatitis-and-eosinophilic-esophagitis/ Wed, 29 Apr 2026 15:05:28 +0000 https://clinicaltrials.eu/trial/study-on-etrasimod-arginine-for-patients-with-ulcerative-colitis-alopecia-areata-atopic-dermatitis-and-eosinophilic-esophagitis/ This clinical trial is focused on studying a group of diseases known as immune-mediated inflammatory disorders. These include conditions like ulcerative colitis, alopecia areata, atopic dermatitis, and eosinophilic esophagitis. The study is testing a medication called Etrasimod Arginine, which is being developed by Pfizer Inc. The medication is being tested in the form of mini tablets, which are small tablets that can be mixed with different foods or water.

The purpose of the study is to learn more about how the body absorbs the Etrasimod Arginine mini tablets when they are mixed with different foods like applesauce, chocolate pudding, yogurt, or just water. The study will also look at how the mini tablets taste when mixed with these foods. Participants in the study will take a single dose of the mini tablets in different forms, and researchers will compare how the body absorbs the medication in each case.

The study involves healthy adult participants who will take part in a series of tests to see how the medication is absorbed and how it tastes. The study will help researchers understand the best way to deliver the medication to patients in the future. Participants will be monitored for any side effects and will provide feedback on the taste and feel of the mini tablets. This information will be used to improve the medication for future use in treating the diseases being studied.

]]> Study on the Use of Viscous Budesonide for Children with Eosinophilic Esophagitis https://clinicaltrials.eu/trial/study-on-the-use-of-viscous-budesonide-for-children-with-eosinophilic-esophagitis/ Wed, 29 Apr 2026 15:02:09 +0000 https://clinicaltrials.eu/trial/study-on-the-use-of-viscous-budesonide-for-children-with-eosinophilic-esophagitis/ This clinical trial is focused on studying Eosinophilic Esophagitis, a condition where a type of white blood cell called eosinophils builds up in the esophagus, causing inflammation and difficulty swallowing. The study will use a new formulation of a medication called Budesonide, which is a type of cortisone-like medicine. Budesonide will be prepared in a special way to make it more effective for this condition.

The purpose of the study is to evaluate how well this new viscous form of Budesonide works in children and adolescents with Eosinophilic Esophagitis. Participants will receive the medication in a liquid form that they will swallow. The study will last for about 12 weeks, during which the effects of the medication on the esophagus will be monitored. This includes checking if the number of eosinophils in the esophagus decreases and if symptoms improve.

Throughout the study, researchers will also keep track of any side effects or adverse events that participants might experience. The goal is to see if this new formulation of Budesonide can effectively reduce the symptoms and inflammation associated with Eosinophilic Esophagitis in young patients.

]]> Title: Study of Solrikitug compared to placebo for adults with Eosinophilic Esophagitis to evaluate its effectiveness and safety https://clinicaltrials.eu/trial/study-on-solrikitug-for-adults-with-eosinophilic-esophagitis-to-assess-efficacy-and-safety/ Wed, 29 Apr 2026 15:02:06 +0000 https://clinicaltrials.eu/trial/study-on-solrikitug-for-adults-with-eosinophilic-esophagitis-to-assess-efficacy-and-safety/ This clinical trial focuses on Eosinophilic Esophagitis (EoE), a chronic inflammatory condition that affects the esophagus (the tube that connects the mouth to the stomach). The study will test a medication called Solrikitug, which is given through subcutaneous injection (an injection under the skin), comparing it with a placebo to determine how well it works in treating inflammation and swallowing difficulties in adults with this condition.

The study consists of two parts. In the first part, participants will receive either Solrikitug or a placebo to evaluate how effectively the medication reduces inflammation in the esophagus and improves swallowing problems. The second part of the study will focus on understanding the long-term safety of the medication. Throughout the study, participants will receive regular medical check-ups and various tests to monitor their condition.

During the trial, participants may receive up to 500 milligrams of Solrikitug per day. The medication will be provided as a powder for injection that will be prepared before use. The study team will monitor participants for any side effects and evaluate how well the treatment works by examining tissue samples from the esophagus and tracking improvement in swallowing ability.

]]> Study on Budesonide Tablets for Treating Eosinophilic Esophagitis in Adults https://clinicaltrials.eu/trial/study-on-budesonide-tablets-for-treating-eosinophilic-esophagitis-in-adults/ Wed, 29 Apr 2026 15:00:32 +0000 https://clinicaltrials.eu/trial/study-on-budesonide-tablets-for-treating-eosinophilic-esophagitis-in-adults/ This clinical trial is focused on studying the treatment of eosinophilic esophagitis, a condition where the esophagus becomes inflamed due to a high number of eosinophils, which are a type of white blood cell. The study is testing the effectiveness and tolerability of budesonide orodispersible tablets, which are designed to dissolve in the mouth. The trial compares two dosing schedules: taking 2 mg once daily versus 1 mg twice daily. The goal is to determine if the once-daily dose is as effective as the twice-daily dose in achieving histological remission, which means reducing the inflammation in the esophagus to a level that is not detectable under a microscope.

Participants in the study will be randomly assigned to one of the two dosing schedules. The study is designed to be double-blind, meaning neither the participants nor the researchers will know which dosing schedule each participant is following. This helps ensure that the results are not biased. The trial will last for a period of six weeks, during which the participants will take the medication and undergo various assessments to monitor their condition and any changes in symptoms.

The primary focus of the study is to see how many participants achieve histological remission. Secondary aspects being observed include changes in the severity of symptoms such as difficulty swallowing (dysphagia) and pain when swallowing (odynophagia), as well as overall symptom severity. The study aims to provide valuable information on the best dosing schedule for treating eosinophilic esophagitis with budesonide orodispersible tablets.

]]> Study on the Effects of EP-104IAR and Tetracosactide for Adults with Eosinophilic Esophagitis https://clinicaltrials.eu/trial/study-on-the-effects-of-ep-104iar-and-tetracosactide-for-adults-with-eosinophilic-esophagitis/ Wed, 29 Apr 2026 14:59:37 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-ep-104iar-and-tetracosactide-for-adults-with-eosinophilic-esophagitis/ This clinical trial is focused on studying a condition called eosinophilic esophagitis, often abbreviated as EoE. EoE is a disease where a type of white blood cell, called eosinophils, builds up in the esophagus, which can lead to inflammation and difficulty swallowing. The trial is testing a treatment known as EP-104IAR, which contains the active substance fluticasone propionate. This medication is given as an injection and is being evaluated for its safety and how it behaves in the body, as well as its effectiveness in treating EoE.

The purpose of the study is to determine how safe and tolerable EP-104IAR is for adults with EoE, and to understand how the body processes the medication. Participants in the study will receive injections of EP-104IAR and will be monitored over a period of time to observe any changes in their condition and to check for any side effects. The study will also involve regular check-ups to measure the levels of the medication in the blood and to assess the overall health of the participants.

Throughout the study, participants will have their symptoms and health monitored at various intervals, including weeks 2, 4, 8, 12, 24, and up to week 52 for some. This will help researchers understand the impact of the treatment on EoE symptoms, such as difficulty swallowing, and to see if there are any improvements in the condition of the esophagus. The trial aims to provide valuable information on the potential benefits and risks of using EP-104IAR for treating eosinophilic esophagitis.

]]> Study on Long-Term Safety of Cendakimab for Adults and Adolescents with Eosinophilic Esophagitis https://clinicaltrials.eu/trial/study-on-long-term-safety-of-cendakimab-for-adults-and-adolescents-with-eosinophilic-esophagitis/ Wed, 29 Apr 2026 14:30:05 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-of-cendakimab-for-adults-and-adolescents-with-eosinophilic-esophagitis/ This clinical trial is focused on studying the long-term safety of a treatment called Cendakimab for individuals with eosinophilic esophagitis. Eosinophilic esophagitis is a condition where a type of white blood cell, called eosinophils, builds up in the esophagus, which can lead to inflammation and difficulty swallowing. The treatment being tested, Cendakimab, is given as a solution for injection under the skin.

The purpose of this study is to evaluate how safe and tolerable Cendakimab is when used over a long period. Participants in the study will receive Cendakimab and will be monitored for any side effects or changes in their health. The study will also look at how the body responds to the treatment, including whether it produces any antibodies against Cendakimab.

Participants in this study include both adults and adolescents who have previously been involved in related studies. The study will continue for several years, allowing researchers to gather comprehensive data on the long-term effects of Cendakimab in treating eosinophilic esophagitis. This information will help determine the safety of using Cendakimab as a treatment option for this condition.

]]> Study on Tezepelumab for Symptom Relief in Patients Aged 12-80 with Eosinophilic Esophagitis https://clinicaltrials.eu/trial/study-on-tezepelumab-for-symptom-relief-in-patients-aged-12-80-with-eosinophilic-esophagitis/ Wed, 29 Apr 2026 14:28:05 +0000 https://clinicaltrials.eu/trial/study-on-tezepelumab-for-symptom-relief-in-patients-aged-12-80-with-eosinophilic-esophagitis/ This clinical trial is focused on studying eosinophilic esophagitis, a rare and chronic condition where the esophagus becomes inflamed due to an immune response to certain foods and airborne particles. This inflammation can cause difficulties in swallowing and other esophageal problems. The study will test the effects of a treatment called tezepelumab, which is given as an injection. Tezepelumab is being compared to a placebo to see how well it works in improving symptoms and reducing inflammation in the esophagus.

The purpose of the study is to evaluate how tezepelumab affects the esophagus in patients with eosinophilic esophagitis. Participants in the study will receive either tezepelumab or a placebo through a subcutaneous injection, which means the injection is given under the skin. The study will monitor changes in symptoms and the condition of the esophagus over time. Participants will be observed for improvements in their symptoms and any changes in the inflammation of their esophagus.

The study will last for a period of time, during which participants will receive regular injections and attend follow-up visits to assess their progress. The goal is to determine if tezepelumab can provide relief from the symptoms of eosinophilic esophagitis and improve the overall health of the esophagus. This research aims to offer new insights into the treatment of this condition and potentially improve the quality of life for those affected by it.

]]> Study on the Effectiveness and Safety of Barzolvolimab in Adults with Active Eosinophilic Esophagitis https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-barzolvolimab-in-adults-with-active-eosinophilic-esophagitis/ Wed, 29 Apr 2026 14:27:07 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-barzolvolimab-in-adults-with-active-eosinophilic-esophagitis/ This clinical trial is focused on studying eosinophilic esophagitis, a condition where a type of white blood cell called eosinophils builds up in the esophagus, leading to inflammation and difficulty swallowing. The study will evaluate the effectiveness and safety of a treatment called Barzolvolimab (CDX-0159), which is a humanized immunoglobulin G1 kappa monoclonal antibody. This treatment is designed to target and reduce the number of certain cells in the esophagus that contribute to the disease. Participants in the study will receive either Barzolvolimab or a placebo, which is a substance with no active medication, to compare the effects.

The purpose of the study is to assess how well Barzolvolimab works in reducing the number of specific cells in the esophagus and to ensure it is safe for use. The study will involve regular visits where participants will receive the treatment through subcutaneous injections, which means the medication is injected under the skin. The study will last for several weeks, during which participants will be monitored for any changes in their condition and any side effects they might experience.

In addition to Barzolvolimab, the study will also use epinephrine, commonly known as adrenaline, which is a chemical used in emergencies to treat severe allergic reactions. This is included as a precautionary measure. The study aims to provide valuable information on the potential benefits of Barzolvolimab for people with eosinophilic esophagitis, helping to improve treatment options for this condition.

]]>